All In Biotech

Drug Trial Radar · NCT01988493

Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma

A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function

Last checked: Nov 20, 2026Latest source record: Aug 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

117

Actual

Start

Jan 6, 2014

Primary completion

Feb 5, 2018

Study completion Dec 3, 2020

Sponsor

Lead sponsor
Merck KGaA, Darmstadt, GermanyIndustry
Sponsor type
Industry
First posted
Nov 20, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line treatment versus sorafenib in subjects with MET+, Barcelona Clinic Liver Cancer (BCLC) Stage C, systemic treatment naive advanced hepatocellular carcinoma (HCC) and Child-Pugh class A liver function.

Conditions

  • Carcinoma, Hepatocellular

Interventions

  • Tepotinib 300 mgDrug

    Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.

  • Tepotinib 500 mgDrug

    Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.

  • Tepotinib 1000 mgDrug

    Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal

  • TepotinibDrug

    Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.

  • SorafenibDrug

    Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b: Number of Participants Experiencing Dose Limiting ToxicityTime frame: Day 1 to Day 21 of Cycle 1 (each cycle is 21 days)
  2. Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: Baseline up to Day 30 after the last dose of study treatment, assessed up to 94 weeks
  3. Phase 2: Time to Progression (TTP) Based on Tumor Assessment by an Independent Review Committee (IRC)Time frame: From randomization to date of the observation of radiological progressive disease, assessed up to maximum 3.8 years

Locations

43 sites in 3 countries. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • 307 Hosptial of PLA

    Beijing, Beijing Municipality, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA

    Fuzhou, Fujian, China

  • Sun Yat-sen University, Cancer Center

    Guangzhou, Guangdong, China

  • Nanfang Hospital

    Guangzhou, Guangdong, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hu'nan, China

  • Nanjing Bayi Hospital

    Nanjing, Jiangsu, China

  • Nanjing First Hospital Affiliated to Nanjing Medical University

    Nanjing, Jiangsu, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • Shanghai Cancer Hospital, Fudan University

    Shanghai, Shanghai Municipality, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China

  • Cancer Hospital, Tianjin Medical University

    Tianjin, Zhejiang, China

  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

    Zhejiang, Zhejiang, China

  • Dong-A University Hospital

    Busan, South Korea

  • Pusan National University Hospital

    Busan, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • Kyungpook National University Hospital

    Daegu, South Korea

  • National Cancer Center

    Goyang-si, South Korea

  • CHA Bundang Medical Center, CHA University

    Seongnam-si, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Kyung Hee University Hospital

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • Severance Hospital, Yonsei University

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Gangnam Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea, Seoul St. Mary's Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Ajou University Hospital

    Suwon, South Korea

  • Pusan National University Yangsan Hospital

    Yangsan, South Korea

  • Changhua Christian Hospital

    Changhua, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Kaohsiung Chang Gung Memorial Hospital

    Kaohsiung City, Taiwan

  • Taichung Veterans General Hospital

    Taichung, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Chi Mei Medical Center, Liou Ying

    Tainan, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.